HIF prolyl hydroxylase domain inhibitor

orally active in anemia model

from structure-based scaffold hop and opt.

ACS Med. Chem. Lett., Jun. 4, 2020

Mitsubishi Tanabe Pharma, Yokohama, JP

Structure of Compound 19 (iron-binder)

“Compound 19” (iron-binder) is an oral inhibitor of the hypoxia-inducible factor (HIF) propyl hydroxylase domain (HIF-PHD), increasing HIF levels to activate EPO transcription and promote hematopoiesis for treatment of anemia.…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: